Vaccine Contract Manufacturing Market By Service Type (Fill & Finish Services, Drug Substance Manufacturing, Packaging Services), By Product Type (Recombinant Vaccines, Viral Vaccines, Bacterial Vaccines, Conjugate Vaccines), By End-User (Biopharmaceutical Companies, Government Agencies, Non-profit Organizations), By Application (Infectious Diseases, Oncology Vaccines, Autoimmune Vaccines), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Vaccine Contract Manufacturing Market was valued at USD 1.9 billion in 2023 and will surpass USD 3.5 billion by 2030; growing at a CAGR of 8.8% during 2024 - 2030.

The global vaccine contract manufacturing market has witnessed significant growth in recent years, driven by increased demand for vaccines, particularly due to global health crises such as the COVID-19 pandemic. The market encompasses a variety of services, including drug substance manufacturing, fill & finish services, and packaging, provided by specialized third-party manufacturers. These services are essential to support the rapidly growing vaccine production requirements, allowing pharmaceutical and biotechnology companies to focus on R&D while relying on contract manufacturers to manage large-scale production.

The vaccine contract manufacturing sector is characterized by the need for high-quality production standards, regulatory compliance, and efficient supply chain management. With increasing focus on personalized medicine and precision vaccines, this market is expected to continue expanding, especially as countries seek to improve their vaccine production capabilities to handle future outbreaks and emerging infectious diseases.

Service Type Segment is Largest Owing to Fill & Finish Services Demand

Fill & finish services have emerged as the largest segment in the vaccine contract manufacturing market. These services include the final stages of vaccine production, where the drug product is filled into vials, syringes, or other delivery devices, followed by sealing, labeling, and packaging. The importance of this service is underscored by its role in ensuring vaccine sterility, integrity, and proper storage, making it a critical component of the vaccine production process.

Fill & finish services have become particularly crucial with the rise in demand for COVID-19 vaccines, which require specialized handling and packaging to maintain their efficacy. The rapid pace of vaccine distribution during global health emergencies has further fueled the need for efficient and scalable fill & finish services, solidifying its position as the largest subsegment in the market.

Product Type Segment is Fastest Growing Due to Recombinant Vaccines

The recombinant vaccines segment is the fastest-growing subsegment within the vaccine contract manufacturing market. Recombinant vaccines are produced using recombinant DNA technology, which involves inserting a gene that encodes an antigen into a host cell. This process results in the production of a protein that is used to stimulate an immune response in the human body.

Recombinant vaccines are gaining popularity due to their ability to target specific pathogens more effectively and their reduced risk of adverse reactions compared to traditional vaccines. With the growing focus on addressing complex diseases such as cancer, infectious diseases, and viral outbreaks, recombinant vaccines are becoming a key area of investment for biopharmaceutical companies. This technological advancement is expected to continue driving the demand for vaccine contract manufacturing services in the coming years.

End-User Segment is Largest in Biopharmaceutical Companies

In terms of end-users, biopharmaceutical companies represent the largest segment in the vaccine contract manufacturing market. These companies are major players in the production of vaccines, investing heavily in research and development, as well as scaling production to meet global demand. Biopharmaceutical companies often turn to contract manufacturers to manage the production of vaccines at scale, particularly when rapid and cost-effective production is essential.

As the vaccine industry continues to expand, biopharmaceutical companies are increasingly relying on contract manufacturing organizations (CMOs) to meet regulatory standards and expedite vaccine delivery timelines. The partnership between these companies and CMOs ensures efficient manufacturing processes, timely delivery, and high-quality vaccines that meet the stringent regulatory requirements of global health authorities.

Application Segment is Largest in Infectious Diseases Vaccines

In the application segment, infectious diseases vaccines are the largest subsegment within the vaccine contract manufacturing market. Vaccines for infectious diseases, such as influenza, measles, and COVID-19, are in high demand globally due to the rising prevalence of infectious diseases and pandemics.

The ability to quickly develop, scale, and distribute vaccines for emerging infectious diseases is a significant driver of this subsegment’s growth. The increasing emphasis on vaccine preparedness and rapid production capabilities in response to global outbreaks further highlights the importance of this segment. Contract manufacturing services play a pivotal role in supporting the large-scale production of these vaccines, ensuring their timely availability to populations worldwide.

Asia-Pacific Region is Fastest Growing Owing to Increasing Vaccine Production Capacity

The Asia-Pacific (APAC) region is the fastest-growing market for vaccine contract manufacturing. This growth can be attributed to the expanding vaccine production capacities in countries like India, China, and South Korea, which have become global hubs for pharmaceutical manufacturing. The region’s increasing focus on self-reliance for vaccine production and its ability to offer competitive pricing and manufacturing efficiencies make it an attractive destination for vaccine contract manufacturers.

Additionally, the growing number of biopharmaceutical companies and government initiatives aimed at boosting vaccine production capabilities in APAC are expected to further accelerate the demand for contract manufacturing services in this region. The rise in healthcare infrastructure investment and the need to address public health emergencies are driving growth in the Asia-Pacific market, making it a key area for future market expansion.

Competitive Landscape and Key Players in the Vaccine Contract Manufacturing Market

The vaccine contract manufacturing market is highly competitive, with key players offering specialized services across the entire vaccine production process, from drug substance manufacturing to fill & finish services. Leading companies include Lonza Group, WuXi AppTec, Samsung Biologics, and Catalent, Inc., among others. These companies leverage their advanced manufacturing facilities, expertise in regulatory compliance, and strong relationships with biopharmaceutical clients to capture a significant share of the market.

As the demand for vaccine production continues to rise, these companies are expanding their production capacities, entering strategic partnerships, and investing in cutting-edge technologies such as next-generation sequencing and mRNA vaccine production. The competitive landscape is characterized by a mix of established players and emerging biotech firms, all vying for market share in a rapidly evolving industry. The ability to scale production, ensure product quality, and comply with rigorous regulatory standards will remain key differentiators in the competitive landscape

List of Leading Companies:

• Bausch Health
• Boehringer Ingelheim
• Catalent, Inc.
• CordenPharma
• Emergent BioSolutions
• GlaxoSmithKline
• Lonza Group AG
• Recipharm AB
• Samsung Biologics
• Sanofi Pasteur
• Serum Institute of India
• Takeda Pharmaceutical Company
• Vaccines Manufacturing, Inc. (VMI)
• Vetter Pharma International
• WuXi AppTec

Recent Developments:

• Lonza Group AG announced the expansion of its manufacturing capabilities in North Carolina to support global COVID-19 vaccine production, including drug substance and fill-finish services.
• WuXi AppTec signed a partnership agreement with a leading biotech firm to support the production of vaccines for infectious diseases, aiming to boost manufacturing capacity for global distribution.
• Samsung Biologics has been awarded a new contract by a European pharmaceutical company to provide large-scale production services for COVID-19 vaccine manufacturing.
• Emergent BioSolutions received regulatory approval for its facility expansion in the United States, increasing its capacity for contract manufacturing of viral vaccines.
• Boehringer Ingelheim has entered into an agreement with a global biotech company to provide contract manufacturing services for the production of mRNA vaccines, contributing to the growing demand for these vaccine types.

Report Scope: